FIRST-PASS METABOLISM,BIOAVAILABILITY
description
Transcript of FIRST-PASS METABOLISM,BIOAVAILABILITY
![Page 1: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/1.jpg)
FIRST-PASS METABOLISM,BIOAVAILABILITY
BY P.RENUKA
M.PHARMACY(1ST Semester)
DEPARTMENT OF INDUSTRIAL PHARMACY
UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES
![Page 2: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/2.jpg)
CONTENTS1. INTRODUCTION2. PHARMACOKINETICS3. BIOAVAILABILITY4. FIRST PASS METABOLISM5. PRIMARY SYSTEMS EFFECT PRESYSTEMIC METABOLISM6. HEPATIC ENZYMES 7. DRUG INTERACTIONS INVOLVING DRUG METABOLISM8. EVIDENCES OF FIRST PASS EFFECT9. LIVER EXTRACTION RATIO10. RELATIONSHIP BETWEEN ABSOLUTE BIOAVAILABILITY AND
LIVER EXTRACTION11. ESTIMATION OF REDUCEDS BIOAVAILABILITY DUE TO LIVER
METABOLISM & VARIABLE BLOOD FLOW12. HEPATIC EXTRACTION RATIOS13. RELATIONSHIP BETWEEN BLOOD FLOW, INTRINSIC CLEARANCE
AND HEPATIC CLEARANCE
![Page 3: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/3.jpg)
14. EFECT OF CHANGING INTRINSIC CLEARANCE & BLOOD FLOW ON HEPATIC EXTRACTION AND ELIMINATION HALF-LIFE AFTER IV & ORAL DOSING
15. EFFECT OF CHANGING BLOOD FLOW ON DRUGS WITH HIGH OR LOW EXTRACTION RATIO
16. PREVENTION OF FIRST PASS METABOLISM 17. CONCLUSIONS18. REFERENCES
![Page 4: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/4.jpg)
PHARMACOKINETICS
It is concerned with the ADME of drugs as elicited by the plasma drug concentration-time profile and its relationship with the dose, dosage form and frequency and route of administration.
![Page 5: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/5.jpg)
Bioavailability is a measurement of rate and extent
of a therapeutically active drug that reaches the
systemic circulation and is available at the site of
action. It is denoted by letter ‘F’
![Page 6: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/6.jpg)
The absolute availability of drug is the systemic availability of a drug after extra vascular administration (e.g., oral, rectal, transdermal, subcutaneous) compared to IV dosing.
The absolute availability of a drug is generally measured by comparing the respective AUCs after extra vascular and IV administration.
ABSOLUTE BIOAVAILABILITY
![Page 7: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/7.jpg)
0
10
20
30
40
50
60
70
0 2 4 6 8 10
Plas
ma
conc
entr
atio
n
Time (hours)
Bioavailability (AUC)o (AUC)iv
=
i.v. route
oral route
![Page 8: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/8.jpg)
FIRST PASS METABOLISM/ FIRSTPASS EFFECTS/
PRESYSTEMIC METABOLISM
It is the phenomenon of drug metabolism. Where the concentration of a drug is greatly reduced before it reaches the systemic circulation
![Page 9: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/9.jpg)
Dose
Destroyed in gut
Notabsorbed
Destroyed by gut wall
Destroyedby liver
tosystemiccirculation
BIOAVAILABILITY
![Page 10: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/10.jpg)
Uptake of orally administered drug proceeds after the stomach passage via the small intestine. In the gut and liver, a series of metabolic transformation occurs.
![Page 11: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/11.jpg)
Primary systems which effect presystemic metabolism
1. Luminal enzymes
2. Gut wall enzymes/ mucosal enzymes
3. Bacterial enzymes
4. Hepatic enzymes.
![Page 12: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/12.jpg)
HEPATIC ENZYMES INVOLVED IN DRUG METABOLISM
MIXED FUNCTION OXIDASES (MFO’s)/ MONOOXYGENASES
Requires both molecular oxygen and the reducing agent NADPH
Electron transfer chain consisting 3 components
1. Heme protein ‘cytochrome p-450’2. Flavoprotein cytochrome p-450
reductase3. Heat stable lipid component
phosphatidylcholine
![Page 13: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/13.jpg)
Cytochrome P450
![Page 14: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/14.jpg)
![Page 15: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/15.jpg)
DRUG INTERACTIONS INVOLVING DRUG METABOLISM
The enzymes involved in the metabolism of drugs may be altered by diet and the co-administration of other drugs and chemicals.
Enzyme induction is a drug- or chemical-stimulated increase in enzyme activity, usually due to an increase in the amount of enzyme present.
Enzyme inhibition may be due to substrate competition or due to direct inhibition of drug-metabolizing enzymes, particularly one of several of the cytochrome P-450 enzymes.
Diet also affects drug-metabolizing enzymes. For example, plasma theophylline concentrations and theophylline clearance in patients on a high-protein diet are lower than in subjects whose diets are high in carbohydrates.
![Page 16: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/16.jpg)
Drug- Grapefruit Juice Interaction
![Page 17: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/17.jpg)
Drug
Drug
CYP3A4Drug
Drug
100%
70%
30%
Drug
Villus
Nucleus
Enterocytes
![Page 18: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/18.jpg)
Nucleus
Drug
Drug
Drug
100%
70%
30%
CYP3A4FC
Drug
Enterocytes
Villus
FC
![Page 19: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/19.jpg)
Time
Dru
g B
lood
Con
cent
ratio
n (A
UC
)
Drug Taken with GJ
Drug Taken without GJ
![Page 20: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/20.jpg)
P. B. Watkins 2003
![Page 21: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/21.jpg)
CYP3A4
100%
80%
20%
Small Intestine
CYP3A4
Drug
DrugCY
P3A
4
10%
Liver
Drug
10%
Drug
Targetover 90% of saquinavir is metabolized by the cytochrome P450 isozyme CYP3A4 {01} . Saquinavir is thought to undergo extensive first-pass metabolism and is rapidly metabolized to a variety of inactive mono- and di-hydroxylated compounds
![Page 22: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/22.jpg)
HEPATIC ELIMINATION OF DRUGS
HEPATIC CLEARANCE
It is the measure of drug elimination by the liver..
may be defined as volume of blood that perfuses
the liver and is cleared of drug per unit of time
![Page 23: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/23.jpg)
EVIDENCES OF FIRSTPASS EFFECTS
For drugs that undergo first-pass effects AUC∞ 0, oral is smaller than AUC∞ 0, IV and F < 1. Drugs such as propranolol, morphine, and nitroglycerin have F values less than 1 because these drugs undergo significant first-pass effects.
Eq. 1
![Page 24: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/24.jpg)
LIVER EXTRACTION RATIOThe liver extraction ratio (ER) provides a direct measurement of drug
removal from the liver after oral administration of a drug.
where Ca is the drug concentration in the blood entering the liver and
Cv is the drug concentration leaving the liver.
Eq. 2
![Page 25: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/25.jpg)
Relationship between Absolute Bioavailability and Liver Extraction
where F is the fraction of bioavailable drug, ER is the drug fraction extracted by the liver, and F″ is the fraction of drug removed by nonhepatic process.
If F″ is assumed to be negligible
After substitution of Equation 1 in 4
Eq. 3
Eq. 4
Eq. 5
![Page 26: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/26.jpg)
Estimation of Reduced Bioavailability Due to Liver Metabolism and Variable Blood Flow
where Cl h is the hepatic clearance of the drug and Q is the effective hepatic blood flow. F' is the bioavailability factor obtained from estimates of liver blood flow and hepatic clearance, ER.
usual effective hepatic blood flow is 1.5 L/min, but it may vary from 1 to 2 L/min depending on diet, food intake, physical activity or drug intake
For the drug propoxyphene hydrochloride, F' has been calculated from hepatic clearance (990 ml/min) and an assumed liver blood flow of 1.53 L/min:
![Page 27: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/27.jpg)
HEPATIC EXTRACTION RATIOS
![Page 28: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/28.jpg)
Relationship between Blood Flow, Intrinsic Clearance, and Hepatic Clearance
The ER may vary from 0 to 1.0. An ER of 0.25 means that 25% of the drug was removed by the liver. If both the ER for the liver and the blood flow to the liver are known, then hepatic clearance may be calculated by the following expression:
For some drugs (such as isoproterenol, lidocaine, and nitroglycerin), the extraction ratio is high (greater than 0.7),
For drugs with very high extraction ratios, the rate of drug metabolism is sensitive to changes in hepatic blood flow. Thus, an increase in blood flow to the liver will increase the rate of drug removal by the organ
Eq. 7
Eq. 8
![Page 29: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/29.jpg)
INTRIINSIC CLEARANCE
Intrinsic clearance (Cl int) is used to describe the total ability of the
liver to metabolize a drug in the absence of flow limitations, reflecting
the inherent activities of the mixed-function oxidases and all other enzymes
Eq. 9
Hepatic clearance changes with blood flow and the intrinsic clearance
of the drug, as described in Equation 9
For drugs with low extraction ratios (eg, theophylline, phenylbutazone
and procainamide), the hepatic clearance is less affected
![Page 30: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/30.jpg)
The relationship between liver blood flow and total hepatic clearance for drugs with varying extraction rates (ER).
![Page 31: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/31.jpg)
Effect of Changing Intrinsic Clearance after IV and Oral Dosing
![Page 32: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/32.jpg)
Effect of Changing Blood Flow on Drugs with High or Low Extraction Ratio
![Page 33: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/33.jpg)
PREVENTION OF FIRSTPASS METABOLISM
1. Route of drug administered may be changed
Various transmucosal non invasive routes of drug administration to bypass presystemic elimination in
GIT / LiverLike ocular delivery nasal delivery pulmonary delivery buccal/ sublingual delivery rectal delivery vaginal delivery
![Page 34: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/34.jpg)
2, alternative routes of administration like suppository, intravenous, intramuscular, inhalation aerosol avoid the first pass effect because they allow drugs to be allowed directly into systemic circulation
3. Another way to overcome the first pass
effect is to either enlarge the dose or
change the drug product to a more rapidly
absorbable dosage form
4. Prodrugs
e.g. sulfasalazine
![Page 35: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/35.jpg)
CONCLUSIONSDrugs given parenterally, transdermally or by inhalation may distribute within the body prior to metabolism by the liver.
But the drugs that are highly metabolized by the liver or by the intestinal mucosal cells demonstrate poor systemic availability when given orally.
In drug design drug candidates may have good drug likeness but fail on first pass metabolism, because it is biochemically selective.
![Page 36: FIRST-PASS METABOLISM,BIOAVAILABILITY](https://reader036.fdocuments.us/reader036/viewer/2022062315/56816448550346895dd60e83/html5/thumbnails/36.jpg)
REFERENCES
1. APPLIED BIOPHARMACEUTICS AND PHARMACOKINETICS: FIFTH EDITION; BY LEON SHARGEL, SUSANNA WU.PANG, ANDREW B.C YU2. BIOPHARMACEUTICS AND CLINICAL PHARMACOKINETICS; FOURTH EDITION; BY MILO GIBALDI.3. BIOPHARMACEUTICS AND PHARMACOKINETICS BY D.M BRAHMANKAR, SUNIL B. JAIASWAL.
WEBSITESWWW.GOOGLE.COM